GSK(GSK) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Sales increased by 7% to over GBP 32 billion, driven by Specialty Medicines which grew by 17% [2] - Core operating profit grew by 11%, and EPS was up by 12% [2] - Cash generation was strong at GBP 8.9 billion, supporting future investments and enabling a dividend upgrade to 66 pence [2][29] - Operating margin increased by 110 basis points, with total accretion at CER reaching 470 basis points over the last four years [30] - Cash generated from operations was GBP 8.9 billion, with free cash flow increasing to GBP 4 billion [31] Business Line Data and Key Metrics Changes - Specialty Medicines sales were up 17%, with significant contributions from respiratory immunology and inflammation, which saw an 18% increase [5] - Oncology sales surged by 43%, with Jemperli sales up by 89% [5][6] - HIV sales grew by 11%, driven by long-acting injectables and foundational oral regimens [9] - Vaccine sales were GBP 9.2 billion, up 2%, with Shingrix sales increasing by 8% [15] - GenMed sales slightly declined, with Trelegy showing strong growth offset by other respiratory products [17] Market Data and Key Metrics Changes - Nucala achieved 10 consecutive years of double-digit growth, with sales reaching GBP 2 billion [5] - The U.S. market for long-acting HIV treatments is projected to grow significantly, with Cabenuva growing by 42% [10] - Shingrix sales in Europe and international markets were strong, while U.S. sales faced challenges due to slowing immunization rates [15] - The U.S. retains a 74% market share in MenB vaccines, with positive signs for PenmenV [15] Company Strategy and Development Direction - The company aims to drive top-line growth by maximizing product launches and accelerating key assets in late-stage portfolios [3] - A focus on simplifying operations and leveraging AI and technology to enhance execution [4] - The strategy includes a commitment to long-acting treatments in HIV, with plans for Q6M treatment regimens [11][49] - Business development remains a core focus, with recent acquisitions aimed at enhancing the pipeline [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued profitable growth for 2026, with guidance for sales growth of 3%-5% and core operating profit growth of 7%-9% [32] - The company is positioned to navigate challenges such as the loss of exclusivity for dolutegravir and aims to evolve as a more product-centric organization [37] - Management highlighted the importance of scientific courage and agility in capitalizing on opportunities [37] Other Important Information - The company has secured 5 FDA approvals and initiated 7 new pivotal trials in 2025 [18] - The Zantac charge taken in 2024 impacted total results, but the settlement process is now materially complete [31] - The company plans to maintain a strong balance sheet with net debt to EBITDA stable at 1.3 times [32] Q&A Session Summary Question: Can you elaborate on R&D commercial strategy in COPD and asthma? - Management discussed the positioning of Nucala, Extensa, and other products in the COPD and asthma markets, emphasizing a strategic approach to address different patient populations [40][43] Question: When could we see the six-monthly treatment and what is the TAM increase? - Management confirmed that Q6M treatment is on track for phase 2B this year, with a significant addressable market for long-acting injectables in HIV treatment [49][51] Question: Update on the launch trajectory for Blenrep? - Initial feedback on Blenrep's launch has been positive, with a systematic opening of accounts and engagement with eye care professionals [58][66] Question: Is the reduction in R&D staff part of a broader program? - Management clarified that the reduction is part of a dynamic approach to resource allocation, focusing on areas with the best return potential [72] Question: How should we think about the launch curve for Extensa? - Management indicated a focus on bio-naive patients for Extensa, aiming to broaden the market and improve patient retention [72]